patients with other supraventricular arrhythmias including ectopic atrial tachycardia and atrial flutter, and, in the single patient with supraventricular and ventricular tachycardia, only the former was controlled. In the single patient with atrial fibrillation complicating the Wolff-Parkinson-White syndrome who received verapamil, sinus rhythm was restored. Side effects were few and mild, with rare exceptions of profound hypotension, bradycardia and asystole; their management is discussed, and reasons are advanced why their occurrence is likely to be related either to the concomitant administration of beta-adrenergic blockers or to the presence of sinoatrial disease. It appears that verapamil is particularly saitable for the treatment of supraventricular tachycardias due to a circus movement as calcium antagonism is likely to be most effective in the N region of the atrioventricular node. VERAPAMIL was originally considered to be a coronary vasodilator (Haas and Hairtfelder, 1962) , and on this basis was introduced for the treatment of cardiac ischaemia (Tschirdewahn and Klepzig, 1963; Hoffmann, 1964) . Under experimental conditions, potent antiarrhythmic activity was noted (Melville, Shister and Huq, 1964; Schmid and Hanna, 1967 ; Kaumann and Aramendia, 1968) and it is now recognized that its antiarrhythmic activity and any action improving cardiac ischaemia is determined by its ability to prevent calcium inflow across the cell membrane (Nayler et al., 1968; Fleckenstein, Doring and Kammermeier, 1968; Nayler and Szeto, 1972; Singh and Vaughan Williams, 1972) . In clinical use its antiarrhythmic properties have been demonstrated by Bender et al. (1966) and, in anaesthetized subjects, by Brichard and Zimmerman (1970) . Given intravenously, it has been shown to have a potent effect in slowing and regularizing the ventricular response in atrial fibrillation (Schamroth, 1971; Schamroth, Krikler and Garrett, 1972) .
In the study reported by Schamroth et 
Methods
Verapamil was administered intravenously as previously described (Schamroth et al., 1972) . A dose of 10 mg was given over a period of 15-30 sec. In all cases the patients were in the recumbent position, a 12-lead electrocardiogram was first recorded, and the arrhythmia was identified. A continuous electrocardiographic recording was started before the injection and continued until sinus rhythm had been restored, or for at least 5 min. The blood pressure was recorded before, immediately after and on several occasions subsequent to the administration of the verapamil.
In the patients studied in the laboratory, intracardiac electrographic recordings were made and stimulation carried out as previously described (Spurrell, Krikler and Sowton, 1973 Fig. 7 in the report by Schamroth et al., 1972) . In another patient, in whom the aetiology was congestive cardiomyopathy, the tachycardia was converted to atrial fibrillation which spontaneously changed to sinus rhythm 1 day later; in the other patients, in whom the arrhythmia was believed to be due to thyroxine overdose in one and to cardiac ischaemia in the other, there was a transient increase in the degree of atrioventricular block. This is similar to our further experience with atrial flutter, which has proved less promising than the original findings (Schamroth et al., 1972) . We have administered verapamil to twenty patients, achieving sinus rhythm in five and a transient increase in the degree of atrioventricular block in the remaining fifteen, without altering the cycle length of the flutter waves in any.
A 61-year-old man who suffered from a dual paroxysmal tachycardia of both supraventricular and ventricular origin (Fig. 4) , possibly due to digitalis intoxication, responded promptly to intravenous verapamil in that the supraventricular tachycardia was completely controlled, but the ventricular tachycardia persisted (Fig. 5) (Fig. 6) . This has the appearance of atrial fibrillation complicating the WolffParkinson-White syndrome, most of the impulses being conducted totally down the anomalous tract. The response to intravenous verapamil was at first slowing of the ventricular response (4 min), then development of junctional rhythm with narrow QRS complexes (6 min), and, after 10 min, restoration of sinus rhythm with the pre-excitation pattern (see also Fig. 7) .
Intracardiac studies
Eighteen patients with A-V junctional tachycardias were given verapamil while in circus-movement tachycardia, and in fifteen patients the tachycardia was terminated within 2-3 min. In the remaining three cases, the cycle length was prolonged in both the anterograde and retrograde directions but reciprocation continued. Cessation of tachycardia could take place with interruption of the circuit either in the anterograde pathway (Fig. 8) or in the retrograde pathway (Fig. 9) within the atrioventricular node. Of these fifteen patients-in whom there was no reason to suspect pre-excitation-the presence of a concealed bypass outside the atrioventricular node was suggested in five by constant ventriculoatrial conduction times which were not influenced by verapamil (Spurrell, Krikler and Sowton, 1974a) .
Eight patients with Wolff-Parkinson-White syndrome were given verapamil while in circus-movement tachycardia during laboratory studies, and in seven of these patients the tachycardia was termi- nated within 2 min. In the remaining patient, a suitably-timed extrasystole was injected in order to disrupt the circuit, as described by Wellens (1971) .
Comment
Whether circus-movement tachycardia is due to a process involving the atrioventricular node alone, or whether the circuit involves an anomalous pathway as well as the A-V node, verapamil appears to be a highly effective antiarrhythmic agent, acting directly on the A-V node. The onset of action is rapid, and the response prompt. Intracardiac studies show that verapamil has a potent effect in prolonging A-V nodal conduction (Puech, 1972a; Husaini et al., 1973; Roy, Spurrell and Sowton, 1974) . However, in a certain number of cases, side effects have been noted, including hypotension, bradycardia and on rare occasions, cardiac arrest (Benaim, 1972; Booth- by, Garrard and Pickering, 1972; Sacks and Kennelly, 1972) . In the majority of such cases, the prior administration of beta-adrenergic blockers appears to have been an important factor. As has been shown by Nayler and Szeto (1972) (Nayler, 1974) .
Another possible mode of adverse reaction to verapamil implies depression of S-A nodal activity. Under normal circumstances, the administration of verapamil has very little if any effect on S-A nodal automaticity (Puech, 1972a; Roy et al., 1974) (Roy et al., 1974) . Atropine 1 mg intravenously should, however, be given if a reaction occurs, followed by intravenous calcium (10-20 ml of 10% solution); an intravenous infusion of isoprenaline may be needed and, rarely, temporary ventricular pacing. The chance of an adverse reaction can be minimized if it can be ensured that the patient has not been receiving a beta-blocker for at least 6 hr prior to the administration of verapamil. Suspicion of sinoatrial disease merits especial caution in the use of verapamil. However, perspective must be maintained, as adverse reactions occur to other antiarrhythmic agents, e.g. beta-adrenergic blockers (Szekely, 1972) (Spurrell et al., 1974b) .
In the vast majority of published reports, results of treatment have been excellent (Abaza et al., 1972; Gotsman et al., 1972; Filias and Zanoni, 1972; Puech, 1972b) . Verapamil has been shown to have an important place in the treatment of paroxysmal A-V nodal tachycardia. Our experience has been confined to its intravenous use and we have not made any systematic assessment of its efficacy when given by mouth for treatment or prophylaxis, though others have reported satisfactory results (Bender. 1970; Abaza et al., 1972; Filias and Zanoni, 1972; Puech, 1972b) . Its preferential action on the A-V node may be due to the fact that its potent calcium antagonism is most sensitively felt in the N region of the node, where a slow Na+-Ca++ channel determines conduction (Zipes, 1973) . Provided precautions are taken in the selection of patients and in the exclusion of those who have recently received betaadrenergic blockers, use of verapamil in supraventricular tachycardias provides an important and useful form of therapy. Whether the mechanism involves the A-V node alone or the A-V node plus an extranodal bypass, verapamil has been shown to be a safe and effective primary agent for the treatment of circus-movement supraventricular tachycardias.
